对二次AML高度特异的突变与ELN有利风险NPM1-突变AML的ELN不利结果有关
Onyee Chan1, Najla Al Ali1, Hammad Tashkandi2
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Blood advances
|January 3, 2024
概括
针对二次急性髓性白血病 (sMut) 特定的突变会使NPM1-突变AML患者的结果恶化. 这种不良预后甚至在有利的风险组中仍然存在,并影响整体存活率,特别是当有可测量的残留疾病存在时.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液癌症,其中遗传突变影响患者的结果.
- 在AML中,NPM1突变很常见,通常表明预后有利.
- 在NPM1-突变AML的背景下,二次AML中常见的二次突变 (sMut) 的预后影响尚未完全理解.
研究的目的:
- 研究NPM1-突变急性髓性白血病 (AML) 患者中二次突变 (sMut) 的预后意义.
- 为了确定sMut是否对有利风险NPM1-突变AML子集的整体存活率 (OS) 有负面影响.
- 评估可测量的残留疾病 (MRD) 状态对同时出现NPM1和sMut.患者的存活率的影响.
主要方法:
- 一项多中心研究分析了233名被诊断为NPM1-突变AML的患者的数据.
- 患者根据二次突变 (sMut) 的存在或不存在进行了分层.
- 评估了整体存活率 (OS) 和可测量的残留疾病 (MRD) 状态,包括在2017年欧洲白血病网络 (ELN) 中的有利风险组.
主要成果:
- 与没有sMut的患者相比,sMut患者的整体存活率 (OS) 显著降低 (15.3 vs 43.7个月;P = .002).
- 这种sMut的不良预后效应在2017年ELN有利风险子组内保持 (14.7个月vs未达到;P<.0001).
- NPM1可测量的残留疾病 (MRD) 阴性与较长的生存期有关,特别是在sMut子组 (MRD阴性:73.9个月与MRD阳性:12.3个月;P=0.0170).
结论:
- 二次突变 (sMut) 与NPM1突变的同时发生使得急性髓性白血病 (AML) 的预后不佳.
- sMut代表了显著的负面预后因素,即使在具有基因有利NPM1突变的患者中也是如此.
- 监测MRD对于评估NPM1突变AML的预后至关重要,特别是在存在sMut.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
107
相关概念视频
Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
